About: Laropiprant     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : owl:Class, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
rdfs:label
  • Laropiprant
rdfs:subClassOf
Concept_In_Subset
Semantic_Type
  • Pharmacologic Substance
Preferred_Name
  • Laropiprant
UMLS_CUI
  • C1871001
CAS_Registry
  • 571170-77-9
Accepted_Therapeutic_Use_For
  • Treatment of atherosclerosis, dyslipidemia, and related conditions when administered with niacin
FDA_UNII_Code
  • G7N11T8O78
Contributing_Source
  • FDA
Chemical_Formula
  • C21H19ClFNO4S
FULL_SYN
  • LaropiprantPTNCI
  • MK0524CNNCI
  • MK-0524CNNCI
  • LAROPIPRANTPTFDAG7N11T8O78
  • (-)-((3R)-4-(4-Chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta(b)indol-3-yl)acetic AcidSNNCI
DEFINITION
  • A prostaglandin D2 receptor (DP1) antagonist with niacin-induced vasodilation inhibiting activity. Laropiprant binds to and inhibits the activity of DP1, a G-protein coupled receptor. Via competing with prostaglandin D2 (PG D2) for binding to DP1, this agent prevents PG D2-induced vasodilation and increased blood flow. As niacin induces the synthesis of PG D2, predominantly in the skin, administration of laropiprant may prevent niacin-induced vasodilation in the skin and facial flushing.NCI
code
  • C87372
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 48 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software